本帖最后由 老马 于 2012-1-13 21:20 编辑 , V$ I% q& S5 | E9 f5 N
% e6 ?) n- H) W0 o* Q爱必妥和阿瓦斯丁的比较2 E" a* _- c8 a* Z+ V( L y
# R- ]- |$ U! Phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
+ [' j/ V# K) h- d
# {+ [4 Z f. Q+ v5 B5 \# m/ ]
' ^" r- {+ n) M& I, w) y
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/) ~1 N/ k2 M4 f( c
==================================================
7 p Q& B. g! S/ n' v% pOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
. F) ~8 k! p0 R/ ?2 s7 F6 KPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( Q+ Q! r! I/ q$ vResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.% i8 R) P u1 v' j
|